Gloperba-Elyxyb Royalty Investors

Gloperba-Elyxyb Royalty Investors is a specialized investment vehicle established to hold and manage royalty interests in specific pharmaceutical assets. The entity is primarily known for its June 2023 royalty purchase agreement with Scilex Holding Company, through which it acquired the rights to a percentage of future net sales of Gloperba and Elyxyb. Gloperba is an FDA-approved oral liquid formulation of colchicine used for the prophylaxis of gout flares, while Elyxyb is an oral liquid celecoxib indicated for the acute treatment of migraine. By providing upfront capital in exchange for revenue interests, the company facilitates the commercialization and market expansion of these established therapeutic products. It operates as a niche financial player within the life sciences sector, focusing on asset-backed financing rather than internal drug discovery.